Milestones
- Orna acquired by Eli LillyFeb 2026Complete.
- ORN-252 clinical development under Eli LillyTarget 2026Current milestone.
Upcoming
- 2026ORN-252 clinical development under Eli Lilly (next)
RetatrutideEli Lilly—Lilly sues six companies selling unauthorised retatrutide, which is not yet approvedTirzepatide (Mounjaro / Zepbound)Eli Lilly—FDA approves Mounjaro to reduce heart attack, stroke and cardiovascular death risk in adults with type 2 diabetesRetatrutideEli Lilly—Lilly to present TRIUMPH-2 at EASD 2026: retatrutide gave large weight loss and A1C cuts in obesity with type 2 diabetesEli Lilly—Eli Lilly's market capitalization passes $1 trillionRetatrutideEli Lilly—Retatrutide TRIUMPH-1: 28.3% mean weight loss at 80 weeks on 12 mg vs 2.2% on placeboVERVE-102 (PCSK9 base editor)Eli Lilly—NEJM publishes Heart-2 Phase 1 results: VERVE-102 lowered LDL by 62% on average at the top dose, lasting at least a yearOrforglipron (Foundayo)Eli Lilly—Lilly to present ACHIEVE-4, its largest and longest Foundayo study in type 2 diabetes, at EASD 2026Orforglipron (Foundayo)Eli Lilly—FDA approves Foundayo (orforglipron), an oral GLP-1 pill for obesity, under a national priority voucherEloralintideEli Lilly—Eli Lilly advances eloralintide (amylin agonist) to phase 3 trials for obesity as monotherapy and add-on to incretin drugsOrforglipron (Foundayo)Eli Lilly—UK authorises orforglipron for weight management and type 2 diabetesEli Lilly—Eli Lilly acquires Orna Therapeutics for up to $2.4 billion to advance in vivo CAR-T cell therapies
ORN-252
by Eli LillyUS
Eli Lilly's in vivo CAR-T therapy using circular RNA and lipid nanoparticles to make patients' own cells into CAR-T cells in the body, designed for B cell-driven autoimmune diseases.
PilotStage 3 of 5
Acquired from Orna Therapeutics (Feb 2026); clinical trial-ready, targeting in vivo CAR-T development.
Checked 10 Oct0 updates this week